GeoVax Labs, Inc. New (GOVX) Stock Price

GOVXStock

$0.64−96.42%52W

Market Cap$3.34M

P/E—

PEG Ratio—

Div yield—

Beta3.73

GOVX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-61.87%

Price vs S&P 500 (4W)-8.61%

VGM Score39.56

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)3.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)212.58%

Cash Flow / Share (Quarterly)$-2.67

Price vs S&P 500 (YTD)-95.92%

Gross Margin (TTM)-31.76%

Net Profit Margin (TTM)-403.80%

EPS (TTM)$-13.92

10-Day Avg Trading Volume1.76M

EPS Excl Extra (TTM)$-13.92

Revenue Growth (5Y)6.42%

EPS (Annual)$-22.40

ROI (Annual)-561.15%

Gross Margin (Annual)25.00%

Net Profit Margin (5Y Avg)-4735.50%

Cash / Share (Quarterly)$0.43

ROA (Last FY)-338.46%

Revenue Growth TTM (YoY)-84.76%

EBITD / Share (TTM)$-8.98

ROE (5Y Avg)-397.04%

Operating Margin (TTM)-407.34%

Cash Flow / Share (Annual)$-13.17

P/B Ratio3.01x

P/B Ratio (Quarterly)2.51x

Net Income / Employee (Annual)$-1,129,700

EV / Revenue (TTM)0.35x

Net Interest Coverage (TTM)-19.93x

ROA (TTM)-394.73%

EPS Incl Extra (Annual)$-22.40

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)1.16x

3-Month Avg Trading Volume3.78M

52-Week Price Return-96.42%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)2.13x

Asset Turnover (Annual)0.39x

52-Week High$20.00

Operating Margin (5Y Avg)-4738.15%

EPS Excl Extra (Annual)$-22.40

CapEx CAGR (5Y)-29.34%

Tangible BV CAGR (5Y)-20.70%

26-Week Price Return-50.63%

Quick Ratio (Annual)1.59x

13-Week Price Return-75.04%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.54x

Enterprise Value$2.16M

Revenue / Share Growth (5Y)-33.36%

Asset Turnover (TTM)0.69x

Book Value / Share Growth (5Y)-43.21%

Revenue / Employee (Annual)$131,000

Inventory Turnover (Annual)5.36x

Pretax Margin (Annual)-862.33%

Cash / Share (Annual)$1.78

3-Month Return Std Dev134.82%

Gross Margin (5Y Avg)-920.72%

Net Income / Employee (TTM)$-1,075,000

ROE (Last FY)-561.15%

Net Interest Coverage (Annual)-2781.44x

EPS Basic Excl Extra (Annual)$-22.40

P/FCF (TTM)12.99x

Receivables Turnover (TTM)7.55x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-13.92

Receivables Turnover (Annual)7.55x

ROI (TTM)-743.66%

P/S Ratio (TTM)0.86x

Pretax Margin (5Y Avg)-4735.50%

Revenue / Share (Annual)$2.60

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-114.73%

Year-to-Date Return-83.97%

5-Day Price Return5.50%

EPS Normalized (Annual)$-22.40

ROA (5Y Avg)-225.35%

Net Profit Margin (Annual)-862.33%

Month-to-Date Return0.75%

Cash Flow / Share (TTM)$-0.90

EBITD / Share (Annual)$-22.51

Operating Margin (Annual)-869.33%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-397.04%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-13.92

P/TBV (Quarterly)3.90x

P/B Ratio (Annual)1.34x

Inventory Turnover (TTM)5.82x

Pretax Margin (TTM)-403.80%

Book Value / Share (Annual)$2.21

Price vs S&P 500 (13W)-77.84%

Beta3.73x

P/FCF (Annual)33.16x

Revenue / Share (TTM)$0.00

ROE (TTM)-743.66%

52-Week Low$0.59

vGradeB

gGradeD

mGradeF

vgmGradeD

GOVX Earnings Surprise History

Q2 25-8.75est. -9.00

Q3 25-7.75est. -6.63

Q1 26-2.62est. -0.84

Q2 26-0.97est. -2.15

GOVX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GOVXGeoVax Labs, Inc. New	B	D	F	$0.64
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About GeoVax Labs, Inc. New

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors using proprietary platforms. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine in human trials, complemented by candidates targeting Monkeypox, hemorrhagic fevers, Zika, and head and neck cancer. The company's approach combines preventive vaccines and gene-directed immunotherapies across a diversified pipeline.